Successful treatment of a woman with relapsing neuromyelitis optica by interferon beta.

Saved in:
Bibliographic Details
Title: Successful treatment of a woman with relapsing neuromyelitis optica by interferon beta.
Authors: Xu, Yan, Zhang, Yao, Ye, Jing, Peng, Bin, Wang, Jian-Ming, Cui, Li-Ying
Source: Neurological Sciences. Aug2012, Vol. 33 Issue 4, p911-913. 3p.
Subjects: Autoimmune diseases in women, Autoimmune disease treatment, Antigens, Interferons, Disease relapse prevention, Preventive medicine, Myelin oligodendrocyte glycoprotein, Drug efficacy
Abstract: Neuromyelitis optica (NMO) is an antibody-mediated disease with the target antigen being the water channel aquaporin-4 (AQP4). More than 90% of NMO patients have relapse. Optimal treatments to prevent recurrence have not been established. Previous reports suggest that interferon beta (IFNB) has not been effective in NMO. However, we present a case of NMO with positive anti-myelin oligodendrocyte glycoprotein (MOG) IgG and anti-AQP4 IgG treated with IFNB-1a successfully. The effect of IFNB on NMO and the role of anti-MOG antibodies in NMO deserve further study. [ABSTRACT FROM AUTHOR]
Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Description
Abstract:Neuromyelitis optica (NMO) is an antibody-mediated disease with the target antigen being the water channel aquaporin-4 (AQP4). More than 90% of NMO patients have relapse. Optimal treatments to prevent recurrence have not been established. Previous reports suggest that interferon beta (IFNB) has not been effective in NMO. However, we present a case of NMO with positive anti-myelin oligodendrocyte glycoprotein (MOG) IgG and anti-AQP4 IgG treated with IFNB-1a successfully. The effect of IFNB on NMO and the role of anti-MOG antibodies in NMO deserve further study. [ABSTRACT FROM AUTHOR]
ISSN:15901874
DOI:10.1007/s10072-011-0849-0